Oncology needs leaders who connect people, champion collaboration, and advance cancer care beyond borders. @montypal brings that vision and commitment Proud to support his candidacy for the @ASCO Board of Directors! #ASCOElection 🗳️ asco.org/about-asco/asco-ove…

@APCCC_Lugano 2026 Consensus is out! 😃🥳👩‍🔬👨‍⚕️ authors.elsevier.com/sd/arti… @Silke_Gillessen @AOmlin @oncodaily @INCMNSZ_Uronco @cdanicas @UroTeragLATAM High-risk localised and locally advanced PC 🔴 PSA recurrece & persistence 🟠 Neoadjuvant systemic therapy for RT & RP 🟢 Testosterone recover & supplementation 🔵 Genetic evaluation 🟣 Bone protection

CONGRESO EUROPEO - Madrid 2026 Dr. Rubén Kowalyszyn, presidente de la Asociación Argentina de Oncología Clínica #esmo26 @myESMO

AI in real world data... Quijotes y Sanchos 🇪🇸! Vision and grounding! #ESMO26 #AAOCDigital

PE-PE trial: pembro + MDT in #RCC Definition of Oligomets: Less than 2️⃣ bone 🦴 met Less than 3️⃣ cm 📏 soft tissue lession Better relapse free survival ⬆️ #ESMO26 @myESMO @drlacovelli

LITSPARK-011: PFS and ORR ✅ benefit of bel + len vs cabo was maintained. While OS favored bel + len, it did not ❌ reach statistical significance @DrDanielHeng @myESMO #ESMO26

Neither addition of HIF-2α inhibitor belzutifan nor of CTLA-4 blockade to pembrolizumab + lenvatinib in advanced #RCC improved efficacy; pembro + lenv remains a 1L SOC. By @DrChoueiri #ESMO26 @myESMO

Presidential symposium 1️⃣!! DASL-HCaP: Darolutamide significantly improved MFS-CI when added to ADT and loco-regional RT for very high-risk localised, or biochemically persistent/recurrent prostate cancer. #ESMO26 @myESMO

It’s with mixed emotions and deep gratitude that I will be leaving USC after 17 years to begin a new exciting chapter @UclaUrology as Director of the Institute of Urologic Oncology and Division Chief of Urologic Oncology. Forever thankful for the trainees, colleagues and patients who have shaped my journey. Grateful to @uroegg and @UCLAHealth leadership for their confidence and vision, and excited to build on their remarkable legacy of excellence.

Presidential symposium 1️⃣!! DeLLphi-305 study: Tarlatamab + durva significantly improved ✅ OS, PFS, and ORR ‼️ in 1LM ES-SCLC @myESMO #ESMO26 a 🆕 standard of care!

Presidential symposium 1️⃣!! Volga trial: ph3 combo neoadjuvant EV + perioperative Durva +/- Treme. Dual primary endpoints of EFS were met. D+EV (HR 0.51) D+T+EV (HR 0.61) ❕#UrothelialCarcinoma #ESMO26 @myESMO @tompowles1 @FAndreMD

Presidential symposium 1️⃣!! Interpath-001: adjuvant INT (intismeram) plus pembro impact in RFS & DMFS for stage II-IV resectable melanoma #ESMO26 @ProfGLongMIA @myESMO #personalizedmedicine

Proteus trial subgroup analysis. Confirms the role of perioperative APA + ADT for the selective HIGH RISK LOCALIZED #prostatecancer #ESMO26 @myESMO

EX-BAT trial by @DiogoAssed @LACOG_group team! Congrats. #ESMO26 @myESMO

Runing to the poster hall #ESMO26

No doubt about the prognostic value of cTDNA in #UrothelialCarcinoma #ESMO26 But.... How about in patients reffusing surgery?? @myESMO